Article: Samuel joins the battle for a tax-free treatment

Five-year-old Samuel does not flinch when doctors inject the plasma-based treatment he needs to fight haemophilia.

It is his father, Kevin Farnill, who worries that Samuel is not getting the best and safest treatment and that is why they will both be attending a tribunal in London today that challenges a decision to impose value- added tax on a purer, artificial clotting agent.

Doctors agree that recombinant Factor VIII, a genetically engineered clotting agent, is purer and safer than the plasma-derived agent and preferable for treating children. But it costs twice as much as the plasma-based treatment and a decision by Customs and Excise to impose VAT on the product this summer made it even ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!